相似文献
1
Extreme body mass index and survival in newly diagnosed multiple myeloma patients.
Blood Cancer J. 2023 Jan 12;13(1):13. doi: 10.1038/s41408-022-00782-7.
2
Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.
Lancet Haematol. 2019 Dec;6(12):e616-e629. doi: 10.1016/S2352-3026(19)30167-X. Epub 2019 Oct 14.
3
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet. 2020 Jan 11;395(10218):132-141. doi: 10.1016/S0140-6736(19)32956-3. Epub 2019 Dec 10.
4
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
5
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
6
Hematology: Bortezomib in newly diagnosed multiple myeloma.
Nat Rev Clin Oncol. 2009 May;6(5):255-6. doi: 10.1038/nrclinonc.2009.47.
7
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
8
Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.
Lancet Oncol. 2010 Nov;11(11):1057-65. doi: 10.1016/S1470-2045(10)70206-0. Epub 2010 Sep 21.
9
Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
Eur J Haematol. 2021 Oct;107(4):466-474. doi: 10.1111/ejh.13683. Epub 2021 Jul 28.
10
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
Eur Radiol. 2017 Dec;27(12):5325-5336. doi: 10.1007/s00330-017-4907-8. Epub 2017 Jun 27.
引用本文的文献
1
AI-based body composition analysis of CT data has the potential to predict disease course in patients with multiple myeloma.
Sci Rep. 2025 Jul 21;15(1):26455. doi: 10.1038/s41598-025-11560-3.
2
Impact of obesity on cancer therapy outcomes: a multicenter cohort study of 30-day mortality and morbidity.
Anticancer Drugs. 2025 Jul 1;36(6):489-494. doi: 10.1097/CAD.0000000000001703. Epub 2025 Apr 10.
3
Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant.
Br J Haematol. 2025 Feb;206(2):763-765. doi: 10.1111/bjh.19937. Epub 2024 Nov 28.
4
The role of nutrition and gut microbiome in the progression of multiple myeloma and its precursor disease.
Front Oncol. 2024 Oct 14;14:1461128. doi: 10.3389/fonc.2024.1461128. eCollection 2024.
5
Adipocytes and metabolism: Contributions to multiple myeloma.
J Bone Oncol. 2024 May 22;46:100609. doi: 10.1016/j.jbo.2024.100609. eCollection 2024 Jun.
6
Association between CTX-1 and Fibulin-1 Serum Levels with Pathogenesis of Multiple Myeloma Cancer.
Asian Pac J Cancer Prev. 2024 May 1;25(5):1599-1605. doi: 10.31557/APJCP.2024.25.5.1599.
7
Design and Rationale of Prolonged Nightly Fasting for Multiple Myeloma Prevention (PROFAST): Protocol for a Randomized Controlled Pilot Trial.
JMIR Res Protoc. 2024 Mar 11;13:e51368. doi: 10.2196/51368.
8
Non-Toxicological Role of Aryl Hydrocarbon Receptor in Obesity-Associated Multiple Myeloma Cell Growth and Survival.
Cancers (Basel). 2023 Nov 1;15(21):5255. doi: 10.3390/cancers15215255.
9
Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups.
Blood Adv. 2024 Jan 9;8(1):236-247. doi: 10.1182/bloodadvances.2023010815.
本文引用的文献
1
A comprehensive review of the impact of obesity on plasma cell disorders.
Leukemia. 2022 Feb;36(2):301-314. doi: 10.1038/s41375-021-01443-7. Epub 2021 Oct 15.
2
A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial.
Leukemia. 2020 Jan;34(1):224-233. doi: 10.1038/s41375-019-0539-0. Epub 2019 Aug 19.
3
Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts.
Br J Cancer. 2018 Apr;118(7):1013-1019. doi: 10.1038/s41416-018-0010-4. Epub 2018 Mar 12.
4
Explaining the Obesity Paradox: The Association between Body Composition and Colorectal Cancer Survival (C-SCANS Study).
Cancer Epidemiol Biomarkers Prev. 2017 Jul;26(7):1008-1015. doi: 10.1158/1055-9965.EPI-17-0200. Epub 2017 May 15.
5
The Evolution of Prognostic Factors in Multiple Myeloma.
Adv Hematol. 2017;2017:4812637. doi: 10.1155/2017/4812637. Epub 2017 Feb 21.
6
Next Steps in Understanding the Obesity Paradox in Cancer.
Cancer Epidemiol Biomarkers Prev. 2017 Jan;26(1):12. doi: 10.1158/1055-9965.EPI-16-0764.
7
Body Fatness and Cancer--Viewpoint of the IARC Working Group.
N Engl J Med. 2016 Aug 25;375(8):794-8. doi: 10.1056/NEJMsr1606602.
8
Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells.
Front Endocrinol (Lausanne). 2016 Jun 17;7:67. doi: 10.3389/fendo.2016.00067. eCollection 2016.
9
Adipocytes contribute to the growth and progression of multiple myeloma: Unraveling obesity related differences in adipocyte signaling.
Cancer Lett. 2016 Sep 28;380(1):114-21. doi: 10.1016/j.canlet.2016.06.010. Epub 2016 Jun 16.
10
Multiple Myeloma Mortality in Relation to Obesity Among African Americans.
J Natl Cancer Inst. 2016 May 4;108(10). doi: 10.1093/jnci/djw120. Print 2016 Oct.
Zotero 插件